BIO-TECHNE DECLARES DIVIDEND
Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended June 30, 2024. The dividend will be payable on August 30, 2024, to shareholders of record as of August 19, 2024. This decision was made by the company's Board of Directors, who will consider future cash dividends on a quarterly basis.
Bio-Techne is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics. With a diverse portfolio of thousands of products, the company generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide.
Bio-Techne (NASDAQ: TECH) ha annunciato un dividendo trimestrale di $0.08 per azione per il trimestre terminato il 30 giugno 2024. Il dividendo sarà pagabile il 30 agosto 2024 agli azionisti registrati fino al 19 agosto 2024. Questa decisione è stata presa dal Consiglio di Amministrazione dell'azienda, che valuterà futuri dividendi in contanti su base trimestrale.
Bio-Techne è un'azienda globale nelle scienze della vita che fornisce strumenti innovativi e reattivi bioattivi per la ricerca e la diagnostica clinica. Con un portafoglio diversificato di migliaia di prodotti, l'azienda ha generato circa $1.2 miliardi in vendite nette nell'esercizio fiscale 2024 e impiega circa 3.100 persone in tutto il mondo.
Bio-Techne (NASDAQ: TECH) ha anunciado un dividendo trimestral de $0.08 por acción para el trimestre finalizado el 30 de junio de 2024. El dividendo será pagadero el 30 de agosto de 2024 a los accionistas registrados hasta el 19 de agosto de 2024. Esta decisión fue tomada por la Junta Directiva de la empresa, que considerará futuros dividendos en efectivo de forma trimestral.
Bio-Techne es una empresa global de ciencias de la vida que proporciona herramientas innovadoras y reactivos bioactivos para la investigación y el diagnóstico clínico. Con un portafolio diverso de miles de productos, la empresa generó aproximadamente $1.2 mil millones en ventas netas en el ejercicio fiscal 2024 y emplea a alrededor de 3,100 personas en todo el mundo.
Bio-Techne (NASDAQ: TECH)는 2024년 6월 30일로 종료된 분기에 대해 주당 $0.08의 분기 배당금을 발표했습니다. 이 배당금은 2024년 8월 30일에 지급될 예정이며, 기록 기준일은 2024년 8월 19일입니다. 이 결정은 회사의 이사회에 의해 이루어졌으며, 이사회는 향후 현금 배당금을 분기별로 고려할 것입니다.
Bio-Techne는 연구 및 임상 진단을 위한 혁신적인 도구와 생물 활성 시약을 제공하는 글로벌 생명 과학 회사입니다. 수천 개의 다양한 제품 포트폴리오를 보유한 이 회사는 회계 연도 2024년 동안 약 $1.2억의 순매출을 발생시켰으며, 전 세계적으로 약 3,100명의 직원을 고용하고 있습니다.
Bio-Techne (NASDAQ: TECH) a annoncé un dividende trimestriel de 0,08 $ par action pour le trimestre se terminant le 30 juin 2024. Le dividende sera payable le 30 août 2024, aux actionnaires enregistrés jusqu'au 19 août 2024. Cette décision a été prise par le Conseil d'Administration de l'entreprise, qui examinera de futurs dividendes en espèces sur une base trimestrielle.
Bio-Techne est une entreprise mondiale des sciences de la vie qui fournit des outils innovants et des réactifs bioactifs pour la recherche et le diagnostic clinique. Avec un portefeuille diversifié de milliers de produits, l'entreprise a généré environ 1,2 milliard de dollars de ventes nettes au cours de l'exercice 2024 et emploie environ 3 100 personnes dans le monde.
Bio-Techne (NASDAQ: TECH) hat eine vierteljährliche Dividende von $0,08 pro Aktie für das zum 30. Juni 2024 endende Quartal angekündigt. Die Dividende wird am 30. August 2024 ausgezahlt, an Aktionäre, die bis zum 19. August 2024 im Buch stehen. Diese Entscheidung wurde vom Vorstand des Unternehmens getroffen, der zukünftige Barausschüttungen vierteljährlich prüfen wird.
Bio-Techne ist ein globales Unternehmen der Lebenswissenschaften, das innovative Werkzeuge und bioaktive Reagenzien für Forschung und klinische Diagnostik bereitstellt. Mit einem vielfältigen Portfolio von Tausenden von Produkten erzielte das Unternehmen im Geschäftsjahr 2024 etwa 1,2 Milliarden US-Dollar Nettoumsatz und beschäftigt weltweit etwa 3.100 Mitarbeiter.
- Declared quarterly dividend of $0.08 per share
- Generated approximately $1.2 billion in net sales for fiscal 2024
- Maintains a large product portfolio serving research and clinical diagnostic markets
- None.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
612-656-4416 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302216347.html
SOURCE Bio-Techne Corporation
FAQ
What is the amount of Bio-Techne's (TECH) quarterly dividend for Q2 2024?
When will Bio-Techne (TECH) pay its Q2 2024 dividend?
What was Bio-Techne's (TECH) net sales for fiscal 2024?
How many employees does Bio-Techne (TECH) have globally?
